Leadership

Leadership

Richard A. Miller, M.D. photo

Richard A. Miller, M.D.

Co-Founder, President and CEO

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School, summa cum laude. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

Leiv Lea photo

Leiv Lea

CHIEF FINANCIAL OFFICER

Mr. Lea served as the Chief Financial Officer of Pharmacyclics from 1998 to 2008. He received a B.S. in agricultural economics from the University of California, Davis, and an M.B.A. from the Anderson School at the University of California, Los Angeles.

jeffery arcara photo

Jeffrey Arcara

Chief Business Officer

Jeffrey Arcara joined Corvus in 2024 as Chief Business Officer to lead the company’s corporate strategy, business development, portfolio strategy, and new product planning. With over 30 years of commercial expertise in the biopharmacuetical industry, Mr. Arcara has broad functional experience across a range of large and small biopharma companies. He previously served as senior vice president, head global marketing & portfolio and strategy for the specialty and biosimilars business at Teva Pharmaceuticals where he held commercial leadership roles of increasing responsibility across several different disease areas. Mr. Arcara holds an MBA from the UCLA Anderson School of Management and a B.A. in Finance and Marketing from University of Wisconsin-Madison.

William Ben Jones, Ph.D. photo

William Ben Jones, Ph.D.

SENIOR VICE PRESIDENT, PHARMACEUTICAL DEVELOPMENT

Dr. Jones was Director of Global Regulatory Affairs in Sanofi U.S.’s oncology business unit from December 2012 to December 2014. From 2008 to March 2012, he was Director of Project Management & Regulatory at Pharmacyclics, where he played a principal role in the development of ibrutinib. Prior to Pharmacyclics, he was Associate Director of Development at Plexxikon and Senior Project Manager at Vertex Pharmaceuticals. Dr. Jones earned a B.S. and a Ph.D. in chemistry from the University of Cincinnati and completed a post-doctoral fellowship at the University of Oxford.

Gabriel Luciano photo

Gabriel Luciano

Vice President Clinical Operations

Mr. Luciano joined Corvus in 2018 and has served as Vice President of Clinical Operations since 2021. He was Senior Director of Clinical Operations at Pharmacyclics from 2012 to 2017 where he played a principal role in the initial clinical development and initial marketing approvals for ibrutinib. From 2008 to 2011, he was Senior Clinical Trial Manager at Seattle Genetics where he supported the initial clinical trial development and initial marketing approvals for brentuximab vedotin. From 1990 to 2008 he held various Clinical Operations positions at Abgenix, Pharmacyclics, Quintiles, Covance and Syntex. Mr. Luciano earned a B.A. in Psychology and Biology from the University of California at Santa Cruz.

Suresh Mahabhashyam, M.D., MPH photo

Suresh Mahabhashyam, M.D., MPH

VICE PRESIDENT CLINICAL DEVELOPMENT

Dr. Mahabhashyam joined Corvus in 2019 and has served as its Vice President of Clinical Development since 2020. He was Vice President Drug Safety at Infinity Pharmaceuticals from 2016 to 2019. Prior to Infinity, he was Senior Medical Director at Alexion from 2012 to 2015. Dr. Mahabhashyam earned his medical degree from Bangalore Medical College and his MPH in epidemiology from University of North Texas Health Science Center.

james rosenbaum photo

James Rosenbaum, M.D.

Senior Vice President of Research

Dr. Rosenbaum, a board-certified rheumatologist and pre-eminent immunologist, previously served as Professor of Ophthalmology, Medicine, and Cell Biology and Chair, Division of Arthritis & Rheumatic Diseases, at Oregon Health & Science University (OHSU) where he held a professorship named in honor of his father, Edward E Rosenbaum. He has authored over 600 publications involving areas including inflammation, autoimmunity, arthritic diseases and the role of the microbiome in immunity. Dr. Rosenbaum is a member of numerous professional societies, including Master of the American College of Rheumatology, Fellow of the Association for Research in Vision and Ophthalmology, the American Federation of Clinical Research, the American Association for the Advancement of Science, and elected member of the American Society for Clinical Investigation and the Association of American Physicians. He received an M.D. from Yale University School of Medicine and graduated with an AB from Harvard University magna cum laude.

Board of Directors

Ian T. Clark

Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in 2016.

During his seven-year tenure as CEO, Ian and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Ian was among the highest rated CEOs by Glassdoor, recognized as the Bay Area’s most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association.

Prior to joining Genentech, Ian held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France.

Currently, Ian is on the board of directors for Takeda, Guardant Health, Olema Oncology and Avrobio.

Ian previously served on the Boards of Forty-Seven, Shire, Kite Pharma, Agios Pharmaceuticals, Dendreon, Solazyme and Vernalis. He was also on the Board of the Biotechnology Industry Association and on the Economic Advisory Council of the 12th District of the Federal Reserve and on the BioFulcrum Board of the Gladstone Institute.

Ian received his bachelor of science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.

Elisha P. (Terry) Gould

Mr. Gould is currently a Partner at Adams Street Partners, LLC, a global private equity firm, and has been employed by Adams Street Partners or its predecessor organizations since 1994. Mr. Gould currently serves on the boards of directors of several private biopharmaceutical and/or healthcare companies. Mr. Gould received an A.B. in Engineering Science from Dartmouth College and an M.B.A. from the Stanford University Graduate School of Business.

Linda S. Grais, M.D., J.D.

Dr. Grais was president and chief executive officer of Ocera Therapeutics, Inc., a biopharma company developing new treatments for serious liver disease, until its acquisition by Mallinckrodt. Prior to that, she was a partner at InterWest Partners, a venture capital firm focused on biotechnology and medical device companies. Previously, Dr. Grais was a founder and executive vice president of Structural GenomiX, Inc., a drug discovery company focusing on new treatments for cancer that was acquired by Eli Lilly & Co. Earlier in her career, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she represented life science companies in venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant professor in the Department of Internal Medicine at the University of California, San Francisco. Dr. Grais currently serves on the board of directors of Arca Biopharma, Inc., ICON plc and Collective Health, a private healthcare services company. Dr. Grais received a B.A. in philosophy from Yale University, an M.D. from Yale Medical School, and a J.D. from Stanford Law School.

Richard A Miller, M.D.

CHAIRMAN

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

Scott W. Morrison

Mr. Morrison was a Partner with Ernst & Young LLP from 1996 to December 2015, where he also served as U.S. Life Sciences Leader from 2002 through December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Mr. Morrison currently serves on the boards of directors of Tarsus Pharmaceuticals, Inc., Ideaya Biosciences, Inc., Zai Labs, Inc. and Vera Therapeutics, Inc. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where he has served on the audit committee since 2002. Mr. Morrison previously served on the boards of directors of the Life Sciences Foundation, a biotechnology nonprofit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Industry Organization (BIO), a trade organization.

Peter Thompson, M.D.

COFOUNDER

Dr. Thompson is currently a Member at OrbiMed Advisors LLC and has over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.

Our Science

We are developing immunology focused medicines that target the most critical cellular elements of the immune system

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases